NEW YORK, December 23, 2014 /PRNewswire/ --
Moments ago, Analysts Review released new research updates concerning several important developing situations including Bristol-Myers (NYSE: BMY), Rite Aid (NYSE: RAD), Boeing (NYSE: BA), TASER (NASDAQ: TASR), and BioCryst (NASDAQ: BCRX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
BMY Research Report: ( http://get.analystsreview.com/pdf/?c=Bristol-Myers&d=23-Dec-2014&s=BMY ),
RAD Research Report: ( http://get.analystsreview.com/pdf/?c=Rite%20Aid&d=23-Dec-2014&s=RAD ),
BA Research Report: ( http://get.analystsreview.com/pdf/?c=Boeing&d=23-Dec-2014&s=BA ),
TASR Research Report: ( http://get.analystsreview.com/pdf/?c=TASER&d=23-Dec-2014&s=TASR ),
BCRX Research Report: ( http://get.analystsreview.com/pdf/?c=BioCryst&d=23-Dec-2014&s=BCRX ).
============
--
Analyst Update: FDA Approval, Quarterly Earnings, Major Contracts and Positive Study Results
Reviewed by: Rohit Tuli, CFA®
The U.S. stock market on Monday booked its fourth straight day of gains as S&P 500 and Dow Jones Industrial Average (DJIA) closed at new records. The rally in U.S. markets was fueled by continued hopes that the Federal Reserve wouldn't be in a rush to raise interest rates. The S&P 500 gained 0.38%, DJIA advanced 0.87%, and the Nasdaq moved up 0.34% at the close of the session. The European markets also ended the day in green, rising for the fifth session in a row, with Greek shares boosted by the Prime Minister's offer to bring pro-European independents into the government. The Asian stocks were mostly higher on Monday as steadiness in crude oil prices and the Russian ruble, along with the Federal Reserve's indication that it will take a slow approach to raising interest rates, lifted the market sentiments.
Bristol-Myers Squibb Co. (Bristol-Myers) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for its Opdivo (nivolumab) injection for the treatment of an advanced form of skin cancer. This also marks the first approval of Opdivo in the U.S. Find out more about the Bristol-Myers' skin cancer drug by clicking on our research report below.
Heading into the final few days of the year 2014, shares of Rite Aid Corporation (Rite Aid) are showing no signs of stopping the rally yet. The stock rose over 5% on Monday, December 22, after rallying nearly 19% in the previous week, thanks to the Company's better-than-expected Q3 FY 2015 results. Click on the report below to know more about what is driving Rite Aid's stock in the volatile market conditions.
State-owned Azerbaijan Airlines becomes the first airline in the Commonwealth of Independent States to operate the Boeing Co.'s (Boeing) 787. The airplane will play a key role in the Baku-based airline's strategic plan to expand its long-haul fleet. Read more about the airline company and the recent orders in our research report on Boeing.
A shot in the arm for TASER International, Inc. (TASER) as the Company bagged smart weapon orders from Ontario Provincial police. Stock up 8.7% in trade and touched a new 52-week high of $26.39, amidst high trading volumes. A total of 5.92 million shares changed hands, higher than the 30-day average trading volume of 4.47 million shares. Read our research report on TASER to know more about the latest orders and Company financials.
BioCryst Pharmaceuticals, Inc. (BioCryst) announced study results for BCX4430 in a non-human primate model of Ebola virus infection; Shares up in after-hours trade. The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is funding the project. To know more about the study results and the recent FDA approval, read our research report on BioCryst.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
